A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets.

Pathogen reduction technologies have been under development for more than two decades and phase III randomized clinical trials (RCTs) using pathogen reduced (PR) blood components have been performed.[1] To date, two PR platelet products have been evaluated using the RCT design: PR platelets prepared by UV illumination in the presence of amotosalen (Intercept Blood System, Cerus) and PR platelets treated with riboflavin plus UV illumination (Mirasol Pathogen Reduction Technology, Terumo BCT). The number of transfusions per patient receiving PR platelets was greater than controls in five amotosalen RCTs[[3], [6], [8]] and in all three riboflavin RCTs (Tables and). All patients were thrombocytopenic with mean pre-platelet transfusion platelet counts ranging from 10 to 18 x 10 SP 9 sp /L. The CCIs in the PR group were lower than in control patients at both 1 and 24 hours following transfusion of amotosalen platelets and riboflavin platelets (Tables and). Four RCTs[[3], [5], [10]] included some patients with solid tumors, where the incidence, nature and duration of bleeding might be different from patients with hematologic malignancies, so this adds some complexity to interpretation of results. [Extracted from the article]